Alder BioPharmaceuticals Merges with H. Lundbeck in $1.95 Billion Deal

Alder BioPharmaceuticals Merges with H. Lundbeck in $1.95 Billion Deal

H. Lundbeck A/S (OMX: LUN), the specialty pharmaceutical giant based in Denmark, announced its first acquisition in over a year. The company revealed it was buying Alder BioPharmaceuticals (NASDAQ: ALDR), a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. One product candidate is ALD1910, a monoclonal antibody for migraine prevention. Lundbeck gains Alder’s eptinezumab product, an investigational monoclonal antibody for migraine prevention that it will develop and launch worldwide in the upcoming years. Lundbeck expects to see significant growth in its brain... Read More »